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The porcine endogenous retrovirus (PERV) Gag protein contains two late (L) domain motifs, PPPY and P(F/S)AP. Using viral release assays
we demonstrate that PPPY is the dominant L domain involved in PERV release. PFAP represents a novel retroviral L domain variant and is defined
by abnormal viral assembly phenotypes visualized by electron microscopy and attenuation of early PERV release as measured by viral genomes.
PSAP is functionally dominant over PFAP in early PERV release. PSAP virions are 3.5-fold more infectious in vitro by TCID50 and in vivo results
in more RNA positive tissues and higher levels of proviral DNA using our human PERV-A receptor (HuPAR-2) transgenic mouse model [Martina,
Y., Marcucci, K.T., Cherqui, S., Szabo, A., Drysdale, T., Srinivisan, U., Wilson, C.A., Patience, C., Salomon, D.R., 2006. Mice transgenic for a
human porcine endogenous retrovirus receptor are susceptible to productive viral infection. J. Virol. 80 (7), 3135–3146]. The functional
hierarchies displayed by PERV L domains, demonstrates that L domain selection in viral evolution exists to promote efficient viral assembly,
release and infectivity in the virus–host context.
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Xenotransplantation, the use of nonhuman cells, tissues or
organs for a human recipient, has the potential to alleviate the
serious and growing human donor organ shortage. Pigs are pre-
sently the most suitable nonhuman donors given their physio-
logical size and compatibility, the use of genetic engineering to
remove immunological barriers (Kolber-Simonds et al., 2004),
and world-wide experience with pig husbandry. A major inter-
national concern is the possibility of cross-species transmission⁎ Corresponding author.
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doi:10.1016/j.virol.2008.02.017of infectious pathogens from animal donors to immunosup-
pressed human transplant patients. In the case of pigs, one major
concern lies with transmission of porcine endogenous retrovirus
(PERV) (Louz et al., 2008).
PERV is a gammaretrovirus present in 10–60 copies in all pig
genomes (van der Laan et al., 2000) and is closely related to the
leukemia-causing viruses, gibbon ape leukemia virus (GALV),
feline leukemia virus (FeLV) and murine leukemia virus (MLV)
(Ericsson et al., 2003). PERVenvelope sequence, in vitro tropism,
and receptor interference assays divides the virus into three classes:
A, B and C (Akiyoshi et al., 1998; Le Tissier et al., 1997; Takeuchi
et al., 1998). PERV-A and -B are able to productively infect human
cell lines in vitro (Le Tissier et al., 1997;Martin et al., 2000;Wilson
et al., 2000) while productive infection of the same lines has not
been demonstrated for PERV-C (Wilson et al., 2000).
A key determinant in establishing a productive viral infec-
tion is the assembly and release of infectious viral particles from
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cross-species transmission to human cells in xenotransplanta-
tion is to understand PERV assembly and release at the mo-
lecular level. Additionally, understanding the basis of virion
assembly and infectivity for PERV, contributes to the overall
knowledge of viral fitness determinants in productive retroviral
infections.
Late (L) domains are one of many components contributing
to efficient viral assembly and release. Three canonical Gag
L domain motifs, PPXY, P(T/S)AP and YXXL, have been
described for many viral families, including retroviruses (Freed,
2002). They are involved in the late stages of viral assembly and
current literature documents three phenotypes for L domain
mutants: 1) incomplete maturation of released particles (Gott-
linger et al., 1991; Le Blanc et al., 2002), 2) reduction of viral
particle release (Demirov et al., 2002; Huang et al., 1995; Wang
et al., 2004; Yuan et al., 1999), and 3) Gag accumulation under
the plasma membrane (Demirov and Freed, 2004; Le Blanc
et al., 2002).
Failed viral assembly phenotypes have been attributed
mechanistically to disruption of the viral L domain motif's in-
teraction with specific host cell proteins that function normally
in a pathway of microvesicular and protein trafficking. Nedd4
binds the PPXY motif in Mason-Pfizer monkey virus (MPMV)
(Gottwein et al., 2003), human T-cell leukemia virus (HTLV-1)
(Bouamr et al., 2003), and Rous sarcoma virus (RSV)
(Kikonyogo et al., 2001). Tumor supressor gene 101 (Tsg101)
binds the P(T/S)AP motif of MPMV (Gottwein et al., 2003) and
human immunodeficiency virus type 1 (HIV-1) (VerPlank et al.,
2001). Alix/AIP1 binds the YPXL motifs of equine infectious
anemia virus (EIAV) (Chen et al., 2005; Martin-Serrano et al.,
2003; Strack et al., 2003) and MLV (Segura-Morales et al.,
2005). Additional L domain sequences, interacting proteins,
and functions for L domains are still being elucidated in
retroviruses as well as other viral families (Licata et al., 2004;
Schmitt et al., 2005; Wirblich et al., 2006).
While some retroviruses have only one L domain [RSV
(PPPY) (Wills et al., 1994; Xiang et al., 1996) and EIAV (YPDL)
(Puffer et al., 1997)], others have two [MPMV (PPPY and
PSAP) (Gottwein et al., 2003), HTLV-1 (PPPY and PTAP)
(Heidecker et al., 2004; Wang et al., 2004), HIV-1 (PTAP
(Gottlinger et al., 1991; Huang et al., 1995) and YPDL (Strack
et al., 2003))], and MLV has three [(PPPY (Yuan et al., 2000),
PSAP and YPAL (Segura-Morales et al., 2005)]. Therefore, it is
logical to ask why some viruses evolve multiple L domains, and,
in this situation, is there an important interaction occurring
between them that determines or regulates viral assembly or
release.
Mutations of the PTAP motif in HIV-1 ablate release (Gott-
linger et al., 1991; Martin-Serrano et al., 2001), while mutation
of P(T/S)AP in MPMVand HTLV impairs but does not prevent
virion production (Gottwein et al., 2003; Heidecker et al., 2004;
Wang et al., 2004). Instead, PPPY is the functionally dominant
domain for MPMV (Gottwein et al., 2003) and HTLV-1(Le
Blanc et al., 2002; Wang et al., 2004). Despite the secondary
role played by P(T/S)AP motif in MPMVand HTLV release, its
conservation suggests that its function is still selected for inviral evolution (Dorweiler et al., 2006) and our new data
indicates a similar status for this domain in PERV.
We determined that Gag of a high-titer infectious PERV-A/C
recombinant clone, PERV-A14/220 (Harrison et al., 2004), has
two L domain motifs—a prototypic PPXY motif and a pre-
viously unidentified P(T/S)AP variant, PFAP, separated by eight
residues. The variant PFAP motif is found in the two published
PERV-C sequences (GenBank AAC16761.1 and AAC16763.1)
while the canonical PSAP motif is found in PERV-A (GenBank
AAM29192). Therefore, PFAP is the L domain sequence con-
tributed to this A/C recombinant clone by PERV-C. PFAP
resembles the previously described P(T/S)AP motif, however,
its role and function as an L domain has not been previously
described in PERV or any other virus.
We compared the functional importance of both L domain
motif pairs, PPPY-PFAP and PPPY-PSAP, in PERV release and
infectivity. Our results demonstrate that PPPY is the primary
L domain required for PERV release, as observed at the level of
viral RNA genomes quantified by RT-qPCR and at the level of
Gag protein quantified by fluorescent-based Western blotting.
Mutation of the P(F/S)AP domains produces a viral release arrest
phenotype observed by electron microscopy, defining their role
as functional L domains. We also show that the PSAP domain
compared to PFAP enhances both early viral release and infec-
tivity in vitro, and in vivo infection of human PERV receptor
transgenic mice. The functional hierarchy of PSAP over PFAP in
early release and infectivity suggests that the prevalence of the
PSAP motif in gammaretroviruses as the secondary L domain is
due to a selection for optimal virion fitness.
Results
The PPPY motif is the dominant L domain for PERV release
A series of PERV mutants was constructed (Fig. 1) to
determine the contributions of: i) PPPY and P(F/S)AP and
ii) PFAP and PSAP L domain motifs in PERV-A14/220 release.
Viral release was measured in the supernatants at the relatively
late time point of 72 h post-transfection. Protein levels were
quantified by densitometry of fluorescent-based Gag Western
blots using a monoclonal anti-PERV Gag antibody and based on
the 24 kDa form of processed Gag (Fig. 2A). We also measured
cellular levels of Gag precursor (Fig. 2B). By normalizing the
amount of Gag detected in the supernatant to the total amount of
Gag protein detected in both cells and supernatants, we created a
metric that we call “average release efficiency” (Fig. 2D) (adapted
from the literature by Gottwein and Krausslich, (2005)). In
parallel, PERV pol RT-qPCR was used to quantify viral genomes
in both cells and supernatants. In this testing, average release
efficiency was determined by normalizing supernatant PERV pol
cDNA copy numbers to the total PERV pol cDNA copy numbers
of both cells and supernatants (Fig. 2E).
The first conclusion is that PPPY is functionally dominant in
PERV release at the level of both Gag protein and viral genome
metrics.Mutation of all four residues of PPPY toAAAA, resulted
in significantly lower average release efficiencies (pb0.05) com-
pared to PPPY-PFAP for both Gag protein and viral genomes
Fig. 1. Schematic of the 524 a.a. Gag protein (bp 4231–5805) present in the high
infectious titer proviral clone PERV-A14/220 (Harrison et al., 2004). Processed
Gag components [matrix (MA), capsid (CA) and nucleocapsid (NC)] are
delineated based on similarity to MLV Gag sequences. The two L domain
motifs, PPPY and PFAP, reside in p12 and are underlined. Mutations were
introduced into the L domains by site-directed mutagenesis. Resulting amino
acid sequences are shown for each construct used to evaluate the role of the
L domains.
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also exhibited similar reductions (Fig. 2E). Additionally, the
average release efficiencies of PPPY-P(F/S)AP and PPPY-AAAA
are equivalent. Thus, P(F/S)AP, alone, is not able to supportFig. 2. Average release efficiency of PERV L domain constructs. Gag protein levels
Gag detected in supernatant virion pellets and (B) precursor Gag detected in cellular
extracts with anti-actin. Actin is a loading control to normalize cellular Gag protein le
of three experiments was averaged to obtain the average release efficiency (%) for G
protein (or genomic RNA) present in the supernatant relative to the total Gag protein
t-tests were applied to determine if the release of mutant constructs was statisticallPERV release. Moreover, in the absence of the PPPY domain,
PTAP, the dominant functional L domain in HIV-1 release, does
not rescue PERVvirion release.We also observed that the average
release efficiencies of all the second L domains (PFAP, PSAP and
PTAP) are equivalent at 72 h (Figs. 2D and E).
The P(F/S)AP motif displays a functional hierarchy early in
PPPY-dominant release
We tested the possibility that at an early time point after
transfection differences in the viral release efficiencies of the
second L domains might be observed. Fig. 3 shows that both
PPPY-PSAP and PPPY-PTAP have significantly higher average
release efficiencies than PPPY-PFAP at 24 h post-transfection. In
addition, PPPY-PTAP has a significantly higher average release
efficiency (pb0.03) compared to PPPY-PSAP. This establishes a
functional hierarchy for PERV release— PTAPNPSAPNPFAP.
An unexpected result was that the presence of the second
L domain appears to attenuate early PERV release. There is
significantly less viral release efficiency comparing either
PPPY-PFAP or PPPY-PSAP to a construct with the second
domain replaced by alanines, PPPY-AAAA (Fig. 3). Attenua-
tion is only observed at the 24-hour time point, as the average
release efficiencies of PPPY-PFAP, PPPY-PSAP and PPPY-
AAAA are equivalent at 72 h post-transfection. Therefore, the
second L domain attenuates early PERV release, PFAP atte-
nuating release more than PSAP, consistent with the observed
functional hierarchy.were determined by densitometry of fluorescence-based Western blots: (A) p24
extracts with mouse monoclonal anti-Gag39, and (C) actin detected in cellular
vels. Viral genome quantification was done by PERV pol RT-qPCR. A minimum
ag protein (D) or viral genomes (E). Release efficiency is an expression of viral
(or viral genomic RNA) present in both the supernatant and the cell. Student's
y significant from the wild-type, PPPY-PFAP (⁎=pb0.05).
Fig. 3. Average release efficiencies of second domain variants in early viral
release. Release efficiencies were determined by viral genome quantification
24 h post-transfection in both supernatants and cells as described in Fig. 2. There
is a functional hierarchy for early viral release in the presence of the dominant
PPPY motif: PTAPNPSAPNPFAP.
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both PPPY and PFAP mutants by electron microscopy
Thin-section electron microscopy was used to visualize 293T
cells 48 h after transfection with either wild-type PPPY-PFAP
(Figs. 4A and D) or the L domain mutants, PPPD-PFAP
(Figs. 4B and E) and PPPY-AAAA (Fig. 4C). All sections were
reviewed and photographed by an independent expert (MW)
blinded to the identities of the samples. PPPD-PFAP shows
thickenings under the plasma membrane at curved surfaces,
which are presumably sites of Gag accumulation prior to virion
budding and consistent with an early budding arrest phenotype
(Le Blanc et al., 2002). Higher magnification reveals viral cores
that do not resemble those of the wild-type PERV (compare
Fig. 4D and E). Nonetheless, budded virions are visualized,
consistent with the results in Fig. 2E for the presence of some
viral genomes in the supernatant. Knocking out the secondFig. 4. Electron micrographs of 293T cells transfected with the following PERV pro
AAAA. Arrows indicate normal virion budding and phenotypes in (A), tethered v
incompletely budded from the cell surface with tethered viral particles (middle ar
compared to PPPY-PFAP (D and E). Micrographs are representative samples of muL domain entirely (PPPY-AAAA), results in a spectrum of late
stage arrest phenotypes including grape-like clusters of virions
at the cell surface (Fig. 4C) as well as tethered viral particles at
the budding sites (see middle arrow). Thus, both L domains of
PERV are involved in virion assembly and release.
PERV L domains enhance, but are not required for viral release
and infectivity
Alanine mutations of both motifs (AAAA-AAAA) result in
significantly lower average release efficiency (pb0.01) com-
pared to PPPY-PFAP (Figs. 2D and E). Nonetheless, we mea-
sured an average of 6.87×104 ±3.15×104 (standard error) viral
genomes of AAAA-AAAA in these supernatants demonstrating
that viral release occurs even in the absence of both L domains.
However, detecting viral genomes in the supernatant does not
directly correlate with infectious virus. Therefore, we tested
supernatants containing AAAA-AAAA virions for infection of
permissive 293T cells. PERV pol genomic DNA copy numbers
were measured at 72 h and 2 weeks post infection. At 72 h,
PERV pol copy numbers in 500 ng of genomic DNA for
AAAA-AAAA were readily detected at 4.8×104 ±2.66×104.
At two weeks the levels increased significantly, consistent with
productive infection (2.1×105±5.5×104). Thus, the L domains
of PERVare not absolutely required for release of an infectious
virion and a productive infection.
PSAP virions are more infectious than PFAP virions in vitro
Given the hierarchy for PERV release, PSAPNPFAP, we
questioned whether there was any difference in the infectivity of
these virions. We tested this possibility with supernatants har-
vested at 72 h, a time at which virion release is equivalent by
both protein and genome quantification. TCID50 values were
determined for PPPY-PFAP, PPPY-PSAP and PPPY-AAAA invirus constructs: (A and D) PPPY-PFAP, (B and E) PPPD-PFAP and (C) PPPY-
iral particles at the cell membrane in (B) and dysmorphic grape-like clusters
row) in (C). Higher magnification images reveal aberrant PPPY-mutant cores
ltiple images obtained for each of the L domain mutant phenotypes.
Fig. 5. PERV pol copies present in 250 ng genomic DNA of 293T and HeLa
cells 72 h after infection with cell-free supernatants from PPPY-PFAP, PPPY-
PSAP or PPPY-AAAA PERV. The graph represents the average of three
independent experiments. A two-tailed Student's t-test was applied to determine
if PERV pol copy numbers present in PPPY-PSAP were statistically different
compared to PPPY-PFAP. PERV pol copy numbers of PPPY-PSAP were 1.4-
fold and 1.8-fold more than PPPY-PFAP in 293T and HeLa cells, respectively.
PPPY-PSAP PERV pol copy numbers were 1.6-fold and 1.3-fold more than
PPPY-PFAP in 293T and HeLa cells, respectively (⁎=pb0.05).
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licates for each dilution). PPPY-PSAP virions are 3.5-fold and
3.8-fold more infectious than PPPY-PFAP and PPPY-AAAA,
respectively.
The greater infectivity of PPPY-PSAP was also established
in single-round infection experiments by qPCR measuring
PERV pol copy numbers present in genomic DNA. We tested
both 293T cells and HeLa 72 h after infection. PERV pol copy
numbers detected in 250 ng of genomic DNA for PPPY-PSAP
are significantly higher compared to PPPY-PFAP and PPPY-
AAAA (pb0.05; Fig. 5). These results further support the
greater infectivity of PPPY-PSAP compared to PPPY-PFAP and
demonstrate that it is not 293T cell-specific.
PSAP virions are more infectious than PFAP virions in vivo
PPPY-PFAP and PPPY-PSAP infectivity was evaluated in
vivo using our human PERV-A receptor 2 (HuPAR-2) trans-
genic mouse model for productive PERV infection (Martina
et al., 2006). The HuPAR2 mouse model tests the L domain
motifs in an environment akin to a natural host infection where
multiple rounds of both viral release and infectivity are required
for a productive infection. Cell-free supernatants from stable
PPPY-PFAP and PPPY-PSAP producer cell lines were used to
infect transgenic and non-transgenic littermates. Mice were
injected intraperitoneally and intravenously with a dose of 104
infectious units of either PPPY-PFAP or PPPY-PSAP, normal-
ized based on the TCID50 values determined immediately prior
to injections. At 4 and 8 weeks after infection, the mice were
sacrificed and multiple tissue compartments were harvested.
PERV pol copy numbers were determined in genomic DNA and
cellular RNA in the various tissues by qPCR and RT-qPCR,
respectively (Table 2).
PERV pol was not detected in the tissues of the non-
transgenic littermates (data not shown). As early as 4 weeks
after infection, PERV pol copy numbers are evident in both
DNA and RNA of the majority of animals and tissues of the
PPPY-PSAP animals at levels consistently higher than the
PPPY-PFAP group. These differences remain clear at 8 weeks.
The in vitro infectivity results are therefore recapitulated in
vivo, indicating that there is a real infectivity advantage for
PPPY-PSAP PERV based on selection of the second L domain.
Discussion
Efficient viral assembly, release and infectivity govern virion
fitness. Here we provide the first report for the relative
contributions of the L domains in PERV Gag to virion fitness.Table 1
Comparison of infectivity in vitro by TCID50 assays
PERV L domains TCID50/ml±SD
a (n=3)
PPPY-PFAP 8.93×103±3.62×103
PPPY-PSAP 3.13×104±6.9×103 b
PPPY-AAAA 8.17×103±6.10×103 b
a SD = standard deviation.
b pb0.03; two-tailed Student's t-test.PERV contains two functional L domains, PPPYand P(F/S)AP,
that both contribute to viral assembly and release. Mutation of
the PFAP domain results in classic L domain cell surface arrest
and abnormal particle assembly phenotypes as observed by
electron microscopy; therefore, we define PFAP as a novel
L domain motif variant of P(T/S)AP. Mutation of the PPPY
domain results in aberrant viral assembly phenotypes, indicat-
ing that PPPY is a functional PERV L domain. However, the
two motifs differentially contribute to early and late viral release
and late particle infectivity. One functional hierarchy is repre-
sented by PPPY over P(F/S)AP for relatively late viral release
(72 h post-transfection). Another functional hierarchy is PSAP
over PFAP for early viral release (24 h post-transfection). Yet
despite the significant reduction in viral genomes released,
double L domain mutant virions, AAAA-AAAA are still infec-
tious. Interestingly, we also demonstrated that PSAP virions are
more infectious as compared to PFAP and AAAA. Therefore, in
the context of viral evolution, L domains are selected for en-
hancing the efficiency of virion release and infectivity, but are
not the sole determinants.
PPPY is the dominant PERV L domain in viral release.
Mutation of the entire domain (AAAA-PFAP) resulted in a
significant reduction of viral particle release measured at the viral
genome and the protein level. Additionally, single residue mu-
tations (PLPY-PFAP and PPPD-PFAP) also resulted in significant
reductions of viral particle release. Our results for PERV are
consistent with the functional dominance of PPPY in other
retroviruses containing more than one L domain. Decreased viral
particle release due to single or multiple residue PPPY mutants
has been demonstrated for HTLV-1 (Heidecker et al., 2004; Le
Blanc et al., 2002;Wang et al., 2004) andMPMV (Gottwein et al.,
2003; Yasuda and Hunter, 1998). Deletion of the PPPY motif in
M-MuLV, a gammaretrovirus like PERV that also contains PSAP
and a third L domain, YPDL (Table 3), reduced release by 80% as
measured by supernatant RT activity (Yuan et al., 2000). The
Table 2
Comparison of infectivity in vivo for wild-type PPPY-PFAP vs. PPPY-PSAP by PERV pol qPCR
DNAa RNAb
4 weeks 4 weeks
PPPY-PFAP PPPY-PSAP PPPY-PFAP PPPY-PSAP
Tissue
PERV
positive
animals c
Average PERV pol
copy number±SEd
PERV
positive
animals
Average PERV pol
copy number±SE
PERV
positive
animals
Average PERV pol
copy number±SE
PERV
positive
animals
Average PERV pol
copy number±SE
Liver 3/7 596±98.1 6/8 1644±404 2/7 327±199 5/8 692±96.2
Lung 0/7 4/7 40.0±6.9 N/A e 0/7
Spleen 0/8 7/8 48.0±13.8 N/A 6/8 766±498
Small bowel 0/8 6/8 363±103 N/A 6/8 1351±535.6
Kidney 8/8 42.5±9.12 6/8 90.0±26.3 4/8 71±8 3/8 43±10.4
Heart 0/8 0/8 N/A N/A
Brain 8/8 986±109 7/8 1043±523.5 5/8 845±429 6/8 512±165
Bone marrow 6/8 17,200±3079 7/8 26,741±3984 6/8 194±46.1 6/8 246±38.9
8 weeks 8 weeks
Liver 1/9 219 7/9 2844±527.3 0/9 5/9 1393±719.1
Lung 1/9 18.7 6/9 29±19 0/9 5/9 78±24
Spleen 0/9 6/9 367±207 N/A 0/9
Small bowel 3/9 197±89.5 4/9 375±63.5 3/9 438±342 4/9 415±222
Kidney 7/9 765±505 8/9 1574±490.7 3/9 184±42.3 4/9 225±36.0
Heart 0/9 6/9 178±64.1 N/A N/A
Brain 5/9 547±106 6/9 1305±336 2/9 298±192 6/9 803±168
Bone marrow 5/9 1642±381.8 7/9 29,947±16,999 5/9 553±132 6/9 1576±293
a Data are expressed as copy number per 2 μg of genomic DNA.
b Data are expressed as copy number per 1 μg of total RNA.
c An animal was designated “PERV positive” if any result was N10 copies in 2 μg of DNA or N10 copies in 1 μg of total RNA (after background subtraction).
d SE = standard error.
e N/A = tissue not analyzed because DNA was demonstrated as negative.
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in viral release is therefore not limited to PERV. In fact, all the
gammaretroviral Gag sequences in the public domain contain the
PPPY motif (Table 3).
The PPPYmotif is also conserved for the deltaretroviruses and
is the dominant L domain required for both bovine leukemia virus
(Wang et al., 2002) and HTLV-1 (Bouamr et al., 2003; Heidecker
et al., 2004; Le Blanc et al., 2002; Wang et al., 2004). Given the
documented dominance of the PPPY motif in viruses with more
than one functional L domain across multiple viral families, weTable 3
Known and proposed gammaretroviral late domains
Virus
Accession
number
PPXY
PERV-A AAF65926 149PPPY151
PERV-C AAC16761 149PPPY152 16
PERV-A14/220a AAT77166 149PPPY152 16
GALV (gibbon ape leukemia virus) P21416 161PPPY164 122PPIY125
MLV (murine leukemia virus) AAB03090 161PPPY164
MuLV (friend murine leukemia virus) NP_040332 162PPPY165
M-MuLV (moloney murine leukemia
virus)
AAB59942 162PPPY
b
165
FeLV (feline leukemia virus) AAA43055 157PPPY160
FSV (feline sarcoma virus) AAA43046 157PPPY160
ARV (avian reticuloendotheliosis
virus)
AAZ57417 154PPPY157
aPresent manuscript.
bPPPY L domain has been documented in the published literature as functional forpropose that this has led to PPPY's conservation in viral evolution.
Further support for this hypothesis is the recent data suggesting
that one step in the endogenization of GALV in the Koala's
genome involved the loss of viral fitness through mutation of its
PPIY motif (Oliveira et al., 2007). However, the secondary
domain in a PPPY-dominant context must also have a function in
order to be carried through the course of viral evolution.
PERV presents two natural variants for the second L domain
sequence, PFAP and PSAP. We have demonstrated a functional
hierarchy of these two domains in early PPPY-dominant releaseL domain type
P(T/S)AP YXXL
161PSAP164
1PFAP164
1PFAP164
115PSAP118
109PTAP112 115PSGP118 129YPAL132
111PSAP114 131YPAL134
111PSAP114 131YPAL135 333YQRL336
168PSGP171
168PSGP171
127PSAP131
viral release and assembly (Yuan et al., 1999).
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greater than PPPY-PFAP in early release (24 h) at the level of
viral genomes. The enhanced efficiency of PSAP over PFAP
could be attributed to the chemical similarity of the serine side-
chain of PSAP to that of threonine in PTAP while the phe-
nylalanine of PFAP lacks the hydroxyl group. This may in-
fluence the binding affinity of viral–host factors involved in
viral release. Consistent with this hypothesis is that binding of
Tsg101 to PTAP has a 7-fold higher affinity than to PSAP
(Pornillos et al., 2003). However, we also have shown that
whatever early gains in efficiency are observed for PSAP over
PFAP, that by 72 h, virion release is equivalent.
An unexpected finding was that PPPY-PSAP is ∼3.5-fold
more infectious than PPPY-PFAP by TCID50. This infectivity
difference is not due to differences in RT activity, as assays of
both PFAP and PSAP virions demonstrated equivalent amounts
(data not shown). Moreover, both 293T and HeLa cells showed
the same relative increase for PPPY-PSAP infection, demon-
strating that the difference is not cell type-dependent. We also
demonstrated that infectivity is greater for PSAP than PFAP in
vivo using our HuPAR-2 transgenic mouse model for PERV
infection (Martina et al., 2006).
Furthermore, PPPY-AAAA demonstrated in vitro infectivity
similar to that of PPPY-PFAP. These results indicate that the
second domain is not required for infectivity. Thus, it is PSAP
that appears to be responsible for the increased infectious virion
fitness demonstrated in vitro and in vivo. Recently, the mutation
of PSAP in vesicular stomatitis virus (VSV) was shown to affect
viral pathogenesis. Mutation of the serine to threonine, yielding
an HIV-1-like PTAP motif, attenuated infection both in vitro
and in vivo (Irie et al., 2007). These data support our ob-
servation that PSAP is playing a role in viral infectivity and
suggest that it is an inherent property of that particular motif
sequence. Excluding PERV, four out of eight known gammar-
etroviral Gag sequences have PSAP in addition to PPPY and
two others have the related motif, PSGP (Table 3). From our
experiments, it would be hypothesized that the prevalence and
evolutionary survival of PSAP as a secondary motif is due to its
role in particle infectivity.
Interestingly, in the presence of the dominant PPPY, both the
PSAP and PFAP second L domains appear to attenuate early
PERV release (24 h; Fig. 3). These results suggest that another
function of the second L domains may be to regulate the pace of
viral assembly or release at the membrane to ensure the com-
pletion of the process and release of fully functional virions.
Mechanistically, this regulation might represent a competition
or an interplay of host cell factors binding the PPPY domain
(e.g. Nedd4) and the P(F/S)AP domain (e.g. Tsg101). There-
fore, future studies could address these questions by studying
which host cell factors are binding PERV L domains and
mapping their potential interactions.
It is important to note that viral genomes are detected in the
supernatant of the double L domain alanine mutant (AAAA-
AAAA), albeit at significantly reduced levels. We demonstrated
that these virions are infectious and the levels increase through
several passages of the infected target cells proving that these
are productive infections. Therefore, L domain-independentmechanisms or presently unknown motifs must contribute to
PERV release under these conditions. The double L domain
mutants of MPMV, HTLV-1 and Ebola Virus VP40 demon-
strated a similar phenomenon of low but measurable viral
release levels (Gottwein et al., 2003; Heidecker et al., 2004;
Neumann et al., 2005). Even HIV-1 lacking the p6 protein,
which contains PTAP, replicates in some T-cell lines and
primary PBMCs, albeit with a delay (Demirov et al., 2002).
Thus, the evidence at present indicates that L domains have
evolved and are selected to enhance the efficiency of viral
assembly and release but they are not absolutely required.
In conclusion, we have demonstrated a hierarchy of
functional L domains for PERV virion release and infectivity.
The dominant role of PERV PPPY in the presence of an
additional L domain motif is consistent with published results
for other multiple L domain-containing viruses. Our results
represent the first functional studies of viral release and
infectivity for the second L domains, P(F/S)AP, in gammare-
troviruses. We demonstrate that these are functional in release
and impact on infectivity in vitro and in vivo. Thus, both
L domains have a role in determining viral fitness and selective
pressures for maintaining a productive viral life cycle, explain-
ing the conservation of multiple L domain motifs in viruses
during viral evolution.
Methods
Cell lines and plasmid constructs
293T and HeLa cells were maintained in DMEM (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(HyClone, Logan, UT), 5% 1 M Hepes (Gibco), 5% 100 mM
sodium pyruvate (Gibco) and 5% 100× penicillin–streptomy-
cin–glutamine (Gibco). Cells were incubated at 37 °C in the
presence of 7% CO2. The wild-type PERV refers to the high
infectious titer PERV-A14/220 clone (PERV-A/C recombinant;
GenBank AY570980) (Harrison et al., 2004) that was a kind gift
from Dr. Y. Takeuchi (University College London). Mutations
were introduced using site-directed mutagenesis with the
QuikChange Mutagenesis kit (Stratagene, Foster City, CA)
according to the manufacturer's protocol.
Viral release assay by RNA genomes
3×106 293Tcells were transfected with 10 μg of wild-type or
mutant PERV-A14/220 proviral plasmid using ProFection
Mammalian Transfection System (Promega, Madison, WI).
Either 24 or 72 h after transfection, 8 ml of supernatant was
filtered (0.45 μm) and ultracentrifuged (23,000 rpm×2 h, 4 °C).
Pelleted viral genomic RNAwas extracted (QIAamp Viral RNA
Mini Kit; Qiagen, Valencia, CA) and purified using the RNeasy
Mini Kit (Qiagen), including on-column DNaseI digestion. 8 μl
of supernatant viral genomic RNA was used for pol-specific
cDNA synthesis with the SuperScript First Strand Synthesis Kit
(Invitrogen; Carlsbad, CA). Cellular RNA was also extracted
using the RNeasy Mini Kit (Qiagen). 2.5 μg of purified cellular
RNA was used for pol-specific cDNA synthesis. A volumetric
644 K.T. Marcucci et al. / Virology 375 (2008) 637–645equivalent of 53.3 μl viral supernatant and a mass equivalent of
11.25 ng of cellular RNAwere used for PERV pol detection by
TaqMan qPCR (Ericsson et al., 2003) on the Applied
Biosystems 7900HT Fast Real Time PCR System (Foster City,
CA). Copy numbers from untransfected 293T cells (negative
control) and supernatants (typically b100 copies) were sub-
tracted from the experimental values of PERV pol copy num-
bers. Average release efficiency was calculated for the RT-qPCR
data using the following equation: (copy # supernatant PERV
pol RNA/copy # supernatant PERV pol RNA+copy # cellular
PERV pol RNA).
Western blot for virion release
3×106 293T cells were transfected with 10 μg of wild-type or
mutant PERV-A14/220 proviral plasmids using ProFection
Mammalian Transfection System (Promega). 72 h after trans-
fection, 8 ml of supernatant was filtered (0.45 μm) and ultra-
centrifuged (23,000 rpm×2 h, 4 °C). Pelleted virions were
resuspended in 100 μl 5× Lamelli loading buffer. 2×106
transfected 293T cells were resuspended in 400 μl 5× Lamelli
loading buffer. 40 μl of the resuspended virion pellet and 25 μl of
the cell preparation in loading buffer were run on a 10%NuPAGE
Bis-Tris gel (Invitrogen). Protein was transferred to Hybond-LFP
PVDF membrane (GE Healthcare, Piscataway, NJ) and immuno-
blotted 1:1000 with the primary mouse anti-Gag39 monoclonal
antibody (kind gift of Dr. G. Byrne (Xu et al., 2003)) in addition to
1:3000 rabbit anti-actin (Sigma) for cellular protein blots.
Secondary antibodies were ECL Plex goat anti-mouse Cy5 and
goat anti-rabbit Cy3 (GE Healthcare) used at 1:1250. Blots were
visualized using the TyphoonTrio Imager (GE Healthcare) and
analyzed using ImageQuant 5.1(GE Healthcare) in terms of
average volume density. We used these results to calculate
average release efficiency in terms of viral protein detected in the
supernatants and cells by replacing the copy # term in the equation
described above with the average volume density.
Electron microscopy
As previously described (Gilula et al., 1978), cells were
grown in 35 mm2 dishes, fixed for 30 min on ice in 2.5%
glutaraldehyde in 0.1 M Na cacodylate buffer (pH7.3). Fol-
lowing treatment with 1% osmium tetroxide for 1 h at room
temperature, each sample was incubated in 0.5% tannic acid in
0.05 M cacodylate buffer for 30 min then rinsed in 1% Na2SO4
for 10 min and then rinsed in 0.1 M cacodylate buffer. The cells
were dehydrated in a graded ethanol series then cleared in
HPMA (2-hydroxypropyl methacrylate) twice for 15 min each
and embedded in LX-112 (Ladd, Burlington VT). After
polymerization at 60 °C for 24 h, the plastic petri dish was
broken away and the thin resin disk was cut up into small pieces
and attached to blank blocks with Superglue. Thin sections were
cut using a diamond knife, mounted on copper slot grids,
stained with uranyl acetate and lead citrate and examined on a
Philips CM-100 electron microscope. Specific images were
recorded on Kodak SO-163 film and negatives were scanned
with a Fujifilm FineScan 2750xl.Determination of TCID50
293T (104 cells/well) were seeded in 48-well plates. Cells
were infected with 4-fold serial dilutions (undiluted to 1:16,384;
6 wells/dilution) of cell-free supernatant from PERV-infected,
stable cell lines. Genomic DNA was extracted after 72 h with
DirectPCR lysis reagent (Viagen, Los Angeles, CA) and
analyzed by PCR for PERV-A/C env using the following: fwd
primer 5′-ATGTCTGCCTTCGATCAGTAATCCC-3′ and rev
primer 5′-CTCAAACCACCCTTGAGTAGTTTCC-3′.
TCID50/ml was calculated using the Karber formula.
Assessment of PERV infection by DNA PCR
2×105 293Tor HeLa cells were seeded in 6-well plates. Eight
hours later, cells were infected with 1 ml of cell-free supernatant
in the presence of 4 μg/ml polybrene and left at 37 °C overnight.
After 16 h, the supernatant was replaced with 2 ml fresh media.
Genomic DNAwas isolated 72 h later and PERV pol copies in
500 ng were determined by PERV pol qPCR.
In vivo infectivity
FVB/Nj mice transgenic for the human PAR-2 (HuPAR-2)
receptor (Martina et al., 2006) were injected both intraperitoneally
and intravenously with cell-free supernatants of either PERVwild-
type (PFAP) or L domain variant (PSAP). The amount of infectious
virus injected was normalized based on TCID50 determinations.
Organs were harvested at 4 and 8 weeks post-exposure. 2 μg of
extracted DNA and 1 μg of extracted RNAwere analyzed for the
presence of PERV pol by qPCR. HuPAR-2 negative littermates
injected with wild-type PERV were used as controls.
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